Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...

Boardrooms and advisory panels across biotech, pharma, digital health, and life sciences suppliers saw a wave of high‑profile additions this month, as companies brought in senior executives, ...

The Coalition for Epidemic Preparedness Innovations (CEPI) has made $60 million available for clinical trials of vaccines for the Bundibugyo species of ebolavirus, with Moderna's mRNA candidate ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows ...

Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in ...

Eli Lilly's Verzenio could offer the first targeted therapy for dedifferentiated liposarcoma (DDLPS), an aggressive cancer that usually needs to be treated with chemotherapy, according to the results ...

Eli Lilly's relentless pipeline-building drive has continued with a licensing agreement for sonefpeglutide, a GLP-2 analogue developed by Hanmi Pharma, across multiple gastrointestinal indications.

Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

At this year’s ASCO Annual Meeting, Pfizer had three major Phase 3 oral presentations: CROWN, TALAPRO-3, and BREAKWATER, each paired with simultaneous publications in leading medical journals.